Investigational Site Number : 170001

Bogotá 110221042

2 studies enrolling now · 12 studies all time

What they study most

Asthma, Fabry Disease, Glycogen Storage Disease Type II, Idiopathic Pulmonary Fibrosis, Mucopolysaccharidosis I (MPS I), Pompe Disease, Rheumatoid Arthritis, Type 2 Diabetes Mellitus

Studies at this site

• Pompe Disease Registry Protocol — Recruiting now
• Fabry Disease Registry & Pregnancy Sub-registry — Recruiting now
• Mucopolysaccharidosis I (MPS I) Registry — Completed
• Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE) — Completed
• Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND) — Completed
• Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis — Completed
• Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications — Completed
• Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma — Completed
• Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest) — Completed
• To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET) — Completed
• An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate — Stopped early
• Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients — Completed